Roivant Sciences (ROIV) AI Stock Analysis

• Market Cap: $19.90B
• Dividend Yield: N/A
• Average Volume (3M): 6.68M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: -83.82%
• EPS Growth: -109.22%
• Country: US
• Employees: 908
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.17
• Shares Outstanding: 715,701,100
• 10 Day Avg. Volume: 6,652,862
• 30 Day Avg. Volume: 6,677,781
• PEG Ratio: 0.41
• Price to Book (P/B): 1.56
• Price to Sales (P/S): 251.93
• P/FCF Ratio: -8.67
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 1.40K
• Enterprise Value/Gross Profit: 1.53K
• Enterprise Value/Ebitda: -18.35
• 1Y Price Target: $33.38
• Price Target Upside: 20.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -1.11
• Revenue Forecast (FY): $9.51M

• Rating: 69 Neutral
• Price Target: $30.00 ▲(7.91% Upside)
• Action: Reiterated Date: 03/04/26
• Date: Action: Reiterated 03/04/26

ROIV scores as moderately attractive, led by strong pipeline/catalyst momentum (earnings call) and significant positive corporate events (Moderna settlement and FDA Priority Review), supported by favorable technical trend. The main constraint is weak financial performance driven by persistent losses and cash burn, with limited valuation support given the negative P/E and no dividend yield provided.

Positive Factors

Strong Cash Runway

A $4.5B consolidated cash balance materially lengthens runway for clinical development and near-term commercial activities, reducing immediate financing pressure. This supports multiple pivotal trials, potential launches and strategic optionality (M&A, buybacks, milestone funding) over the next 2–3 years.

Major Patent Settlement

A large, mostly-cash patent settlement delivers non-dilutive capital and removes a material legal overhang. It also validates Genevant’s LNP IP, strengthening the company’s technology credibility and freeing management to deploy proceeds toward trials, commercialization and shareholder-return programs.

Regulatory Progress for Brepocitinib

Priority Review and an accepted NDA for dermatomyositis shorten regulatory timelines and raise the likelihood of a near-term U.S. launch. If approved, brepocitinib becomes a first-in-class targeted therapy in a high-unmet-need orphan indication, creating a durable commercial foothold across related indications.

Negative Factors

Negative Cash Generation

Persistent negative operating and free cash flow means the business cannot self-fund development from operations. Even with current cash, continued burn elevates reliance on settlements, partnerships or capital markets, increasing execution and dilution risk if clinical timelines slip or commercial launches are delayed.

Volatile, Contracting Revenue

Material revenue contraction and recurring operating losses indicate weak near-term commercial traction and an unstable revenue base. Even with high gross margins, negative net margins and uneven top-line trends undermine sustainable internal funding and heighten dependence on one-time events or partner cashflows.

Clinical Execution Risk

Key Phase II results derive from very small cohorts with baseline imbalances, so effect sizes may not hold in larger, global Phase III trials. This elevates regulatory and execution risk: failed replication could delay approvals, reduce commercial prospects and necessitate additional costly trials.

Roivant Sciences Business Overview & Revenue Model

Company Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

How the Company Makes Money

Roivant Sciences generates revenue primarily through the development and commercialization of pharmaceutical products. The company makes money from several key revenue streams, including milestone payments from collaborations with pharmaceutical companies, royalties on product sales from its subsidiaries, and potential revenues from licensing agreements. Roivant often partners with larger pharmaceutical companies to co-develop drugs, which can provide upfront payments and shared profits. Additionally, the company may receive funding from investors and venture capitalists to support its research and development activities, further contributing to its financial resources.

Roivant Sciences Financial Statement Overview

Summary

Financials are mixed and skew weak: volatile/contracting revenue (~35% TTM decline) and deeply negative profitability with substantial operating losses. Cash flow is consistently negative (ongoing cash burn), partially offset by a strong, low-leverage balance sheet (debt-to-equity ~2%) that provides runway.

Income Statement

Revenue has been volatile and is contracting, with TTM (Trailing-Twelve-Months) revenue down ~35% and multiple years of uneven growth. Despite very strong gross margins (mid‑90% range in recent periods), profitability is weak: TTM net margin is deeply negative and operating losses remain substantial. The 2024 annual period shows an outsized net profit that looks non-recurring versus the surrounding loss-making years, which reduces confidence in earnings consistency.

Balance Sheet

The balance sheet is a relative strength. Leverage is low, with debt-to-equity around ~2% in the latest annual and TTM (Trailing-Twelve-Months) periods, and equity is sizeable versus total assets. While returns on equity are negative in most periods (reflecting ongoing losses), the company appears well-capitalized with limited balance-sheet debt risk.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow consistently negative across all shown periods, indicating ongoing cash burn. Free cash flow deterioration in TTM (Trailing-Twelve-Months) (down ~2% vs the prior period) adds pressure, and cash outflows are not yet stabilizing. While cash burn tracks reported losses in direction, the business has not demonstrated sustainable cash self-funding.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	13.31M	29.05M	32.71M	61.28M	55.29M	23.80M
Gross Profit	12.14M	28.14M	31.11M	48.15M	46.32M	21.74M
EBITDA	-1.02B	-1.10B	-802.89M	-1.18B	-910.77M	-720.58M
Net Income	-809.24M	-171.98M	4.35B	-1.01B	-845.26M	-809.23M
Balance Sheet
Total Assets	5.23B	5.44B	7.22B	2.39B	2.59B	2.69B
Cash, Cash Equivalents and Short-Term Investments	4.53B	4.89B	6.54B	1.68B	2.06B	2.13B
Total Debt	207.44M	100.17M	499.75M	481.40M	283.89M	244.98M
Total Liabilities	251.14M	249.74M	773.95M	782.02M	523.70M	527.69M
Stockholders Equity	4.27B	4.69B	5.97B	1.16B	1.66B	1.90B
Cash Flow
Free Cash Flow	-766.86M	-844.05M	-766.65M	-856.08M	-695.16M	-557.94M
Operating Cash Flow	-759.10M	-839.45M	-765.27M	-843.39M	-677.73M	-552.14M
Investing Cash Flow	257.62M	-1.77B	5.20B	-44.27M	303.30M	-31.70M
Financing Cash Flow	-13.39M	-1.22B	419.36M	499.46M	306.79M	456.26M

Roivant Sciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 27.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ROIV, the sentiment is Neutral. The current price of 27.8 is below the 20-day moving average (MA) of 28.53, above the 50-day MA of 25.56, and above the 200-day MA of 18.01, indicating a neutral trend. The MACD of 0.77 indicates Positive momentum. The RSI at 51.53 is Neutral, neither overbought nor oversold. The STOCH value of 12.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ROIV.

Roivant Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HALO	71 Outperform	$7.51B	25.45	92.67%	―	31.19%	59.01%
ROIV	69 Neutral	$19.90B	-14.22	-18.32%	―	-83.82%	-109.22%
JAZZ	69 Neutral	$11.11B	12.74	-8.82%	―	4.14%	-179.96%
CORT	67 Neutral	$3.54B	36.27	15.25%	―	17.92%	-26.13%
TECH	65 Neutral	$7.95B	60.28	4.10%	0.54%	3.85%	-48.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Roivant Sciences Corporate Events

Roivant Subsidiary Reaches Major Global Patent Settlement

On March 3, 2026, Roivant’s subsidiary Genevant Sciences and partner Arbutus Biopharma reached a $2.25 billion global settlement with Moderna to resolve all U.S. and international patent litigation over Moderna’s use of their lipid nanoparticle delivery technology in COVID-19 vaccines, including Spikevax. The deal includes a $950 million upfront payment due by July 8, 2026, a further contingent payment of up to $1.3 billion linked to the outcome of Moderna’s appeal on Section 1498, and Moderna’s consent to judgments of infringement and no invalidity on four patents.

As part of the settlement, Genevant and Arbutus will grant Moderna a fully paid-up, royalty-free, irrevocable global non-exclusive license and covenant not to sue covering SM-102-based LNP formulations in certain mRNA infectious-disease vaccines, ending all related patent disputes between the parties. Roivant highlighted that, if fully realized, this would be one of the largest patent settlements in the pharmaceutical sector, bolsters the credibility of its LNP intellectual property amid ongoing Pfizer/BioNTech litigation, and supports capital allocation moves such as a $1 billion share repurchase program approved by its board.

The most recent analyst rating on (ROIV) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.

Roivant’s Priovant Unit Gains FDA Priority Review for Brepocitinib

On March 3, 2026, Roivant subsidiary Priovant Therapeutics said the U.S. Food and Drug Administration accepted its New Drug Application for brepocitinib to treat dermatomyositis and granted the filing Priority Review. The FDA set a Prescription Drug User Fee Act target action date in the third quarter of 2026, positioning brepocitinib for a potential U.S. launch at the end of September 2026 if approved.

The Priority Review is backed by positive Phase 3 VALOR trial data, the largest and longest interventional dermatomyositis study, in which brepocitinib 30 mg showed statistically significant and clinically meaningful benefits across primary and key secondary endpoints versus placebo. If approved, brepocitinib would become the first targeted therapy for dermatomyositis, potentially reshaping care for patients reliant on chronic high-dose steroids and enhancing Roivant’s presence in autoimmune therapeutics.

Priovant reported that serious infections were more frequent with brepocitinib 30 mg than placebo but were generally manageable, while malignancies, cardiovascular and thromboembolic events occurred more often in the placebo arm, supporting a safety profile comparable to existing JAK and TYK2 inhibitors. The breadth of the VALOR safety database and inclusion of patients with significant comorbidities may bolster regulatory confidence and strengthen the drug’s commercial case in a high unmet-need market.

The most recent analyst rating on (ROIV) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.

Roivant Sciences Highlights Pipeline Progress at Investor Day

On December 11, 2025, Roivant Sciences hosted its Investor Day, highlighting significant progress in its pipeline and outlining its growth strategy. The company announced plans for multiple product launches and filings over the next three years, including brepocitinib for dermatomyositis, with a commercial launch expected in early 2027. Roivant also reported positive updates on clinical trials, including accelerated timelines for brepocitinib in non-infectious uveitis and cutaneous sarcoidosis, as well as the IMVT-1402 trial for rheumatoid arthritis. Additionally, Roivant’s financing efforts have extended Immunovant’s cash runway to support the launch of IMVT-1402 in Graves’ disease, positioning the company for long-term shareholder value creation.

The most recent analyst rating on (ROIV) stock is a Hold with a $22.50 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.